Opioids - Short Acting And Anti-abuse Technologies Set To Fragment And Grow The Market

PRLog (Press Release) – May 20, 2008 – http://www.companiesandmarkets.com adds new report - Commercial and Pipeline Insight - Opioids - Short acting and anti-abuse technologies set to fragment and grow the market


http://www.companiesandmarkets.com/Summary-Market-Report/Commercial-and-Pipeline-Insight-Opioids-Short-acting-and-anti-abuse-technologies-set-to-fragment-and-grow-the-market-30321.asp

The opioid market is currently valued at $7.7 billion and is set to increase over the next 10 years at a CAGR of 2.4%. Despite this market being exclusively comprised of old genericized molecules, novel formulations and delivery methods have stimulated growth over the last 5 years. This growth is set to continue as current market
players instigate lifecycle management strategies to retain value.

Scope

Sales volume and value forecasts to 2017 of marketed brands, generics, and key late-stage pipeline drugs.
Analysis of patient potential, unmet needs and clinical trial design in the opioid market.
Overview of key marketed brands, late- and early-stage pipeline drugs.
Identification of future market events that are expected to affect opioid revenues.

Highlights

Short-acting opioids represent good in-licensing opportunities for companies with large sales and marketing resources. This market is expected to triple in value over the next 10 years, driven by Cephalon''s Fentora for use in breakthrough pain, and supported by other new short-acting fentanyl formulations.

The long-acting opioid market was valued at over $3 billion in 2007, and is due to grow until the patent expiry of market leader OxyContin in 2011. After a short lived decline, market growth will be stimulated by the launch of anti-abuse formulations, a technical development anticipated to create a $1 billion market.

The topical market represents an opportunity for companies to enter a comparatively underserved market. Although Johnson and Johnson''s market leading Duragesic (fentanyl patch) has faced generic opposition since 2005, sales remain relatively strong due to brand strength and the lack of branded competition.

Reasons to Purchase

Benchmark key late-stage pipeline opioids against current market leading brands.
Assess region-specific (US, Japan, 5EU) sales forecasts of key late-stage pipeline drugs and marketed brands.
Understand unmet needs and opportunities in the opioid market based on key opinion leader comments.

http://www.companiesandmarkets.com/Summary-Market-Report ...